Atossa Therapeutics Inc Stock Price, News & Analysis

Atossa Therapeutics (Nasdaq: ATOS) has announced the enrollment of the first cohort in a Phase 1 clinical study for its nasal spray drug candidate, AT-301, aimed at treating COVID-19. The initial cohort includes 8 healthy participants who received either a placebo or the active drug. The study, conducted in Australia, is designed to evaluate the safety and tolerability of AT-301. The company aims to complete enrollment quickly, emphasizing the potential of AT-301 to act as a protective barrier against COVID-19, which could significantly impact public health if successful.

Atossa Therapeutics (NASDAQ: ATOS) announced its Q2 2020 financial results, reporting no sustainable revenue during the quarter. Operating expenses decreased by 46% to approximately $3.94 million, primarily due to reduced research and administrative costs. Atossa received approval for a Phase 1 clinical study of its COVID-19 nasal spray, AT-301, in Australia, and reported promising in vitro results for its therapies. The company has approximately $7.5 million in cash, bolstered by an additional $4.3 million raised in July.

Atossa Therapeutics (NASDAQ: ATOS) has received ethics committee approval to initiate a Phase 1 clinical study in Australia for AT-301, a nasal spray drug aimed at treating COVID-19. Enrollment is expected to start within 30 days. The drug's unique mechanism targets the nasal cavity to enhance protection and potentially lower symptoms of COVID-19. The study will assess safety and tolerability in 32 participants and could influence future FDA applications. With rising COVID-19 cases in Australia, the trial is timely and significant for public health.

Atossa Therapeutics (Nasdaq: ATOS) has announced positive interim findings from an Expanded Access study of its oral Endoxifen for breast cancer treatment, which shows no recurrence of cancer in a patient after 18 months. The treatment did not cause common side effects associated with tamoxifen, and significant reductions in tumor markers Ki-67 (50%) and ER+ cells (22%) were observed. A Phase 2 study is ongoing, focusing on newly diagnosed patients, with all interim patients showing considerable Ki-67 reduction.

Atossa Therapeutics, Inc. (Nasdaq: ATOS) announces a webinar on July 30, 2020, hosted by CEO Dr. Steven Quay. The 30-minute event will discuss the company's breast cancer programs and advancements in two COVID-19 treatments. Registration is free via Tribe Public's website. Dr. Quay, a prominent figure in medical research, holds multiple patents and has contributed significantly to COVID-19 and breast cancer solutions. The event aims to provide insights into Atossa's progress and engage with investors.

Atossa Therapeutics (NASDAQ: ATOS) has contracted with Avance Clinical to conduct a clinical study of its nasal spray drug candidate, AT-301, aimed at treating COVID-19 in non-hospitalized patients. The double-blinded, randomized, placebo-controlled study will evaluate the safety of AT-301 in 32 healthy adults. The primary goal is to assess tolerability and local irritation, while secondary objectives include bronchospasm evaluations. Atossa plans to file for further regulatory approvals and aims to begin the study soon. The company has also filed provisional patents for AT-301.

Atossa Therapeutics (Nasdaq: ATOS) has announced positive in vitro results for its COVID-19 nasal spray, AT-301. The drug candidate demonstrated the ability to inhibit SARS-CoV-2 infectivity in VERO cells, suggesting potential efficacy in blocking virus entry into nasal cells. AT-301 aims to create a protective mucosal barrier in the nasal cavity, which could lower COVID-19 symptoms and infectivity. A Phase 1 clinical study is expected to commence soon. Atossa has filed provisional patents related to AT-301's formulation and methods of use.

Atossa Therapeutics, Inc. (Nasdaq: ATOS) has announced the hiring of key personnel to enhance its clinical, regulatory, and chemistry manufacturing capabilities. Key hires include Heather Fraser, Ph.D., as vice president of clinical, regulatory and CMC; Natalie Farris, MS, as senior director of CMC; and Devon Payne as director of clinical operations. CEO Steven Quay emphasized that these acquisitions will accelerate the company's development pipeline, focusing on breast cancer and COVID-19 treatments, enhancing their strategic value creation efforts.

Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced promising in vitro test results for its COVID-19 drug candidate, AT-H201. The study indicates that AT-H201 significantly inhibits SARS-CoV-2 infectivity in VERO cells, showing it to be at least four times more potent than remdesivir and 20 times more potent than hydroxychloroquine. A provisional patent has been filed for AT-H201, although further safety and efficacy studies, as well as regulatory approvals, are required before commercialization.